Nakazawa F, Koyama T, Saito T, Shibakura M, Yoshinaga H, Chung D H, Kamiyama R, Hirosawa S
School of Allied Health Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Br J Haematol. 1999 Aug;106(2):416-20. doi: 10.1046/j.1365-2141.1999.01567.x.
Thrombomodulin (TM) is an endothelial cell glycoprotein that acts as an anticoagulant. Mutation in the TM gene is a potential risk factor for thrombosis. The first TM mutation identified was a heterozygous substitution of T for G at nucleotide position 1456, which predicted Asp468 with Tyr in a Ser/Thr-rich domain. To evaluate the reported TM gene mutation as a possible cause of thrombosis, we transiently tranfected a vector for TM gene carrying the mutation to mammalian COS7 cells. TM antigen levels in lysates of cells transfected with variant TM were comparable to those in preparations of normal TM. The TM cofactor activity for protein C (PC) activation on the variant TM-expressing cells was similar to that of the control. The Michaelis constant Km and Vmax. of variant TM for PC activation were shown to be similar compared to those of normal TM. The affinity of each TM for thrombin in PC activation was also similar. We obtained several stable cell lines expressing normal and variant TM. Lysate of the cell lines with normal and variant TM genes had a similar expression level of TM antigen. Pulse-chase analysis showed that normal and variant TM were glycosylated and resistant to endoglycosidase H, indicating that the variant TM was expressed on the cell surface in a mature form. Variant TM protein is apparently expressed on the cell surface with normal cofactor activity for PC activation. It is unlikely that the TM variant directly causes thrombosis by mechanism of reduced expression or impaired cofactor activity for PC activation, which comprises a major anticoagulant activity of TM.
血栓调节蛋白(TM)是一种具有抗凝作用的内皮细胞糖蛋白。TM基因突变是血栓形成的一个潜在危险因素。首次鉴定出的TM突变是核苷酸位置1456处T被G杂合取代,这在富含丝氨酸/苏氨酸的结构域中预测将天冬氨酸468替换为酪氨酸。为了评估所报道的TM基因突变作为血栓形成可能原因的情况,我们将携带该突变的TM基因载体瞬时转染至哺乳动物COS7细胞。转染了变异型TM的细胞裂解物中的TM抗原水平与正常TM制剂中的相当。表达变异型TM的细胞上用于蛋白C(PC)激活的TM辅因子活性与对照相似。与正常TM相比,变异型TM激活PC的米氏常数Km和Vmax显示相似。在PC激活过程中,每种TM对凝血酶的亲和力也相似。我们获得了几个表达正常和变异型TM的稳定细胞系。具有正常和变异型TM基因的细胞系裂解物中TM抗原的表达水平相似。脉冲追踪分析表明,正常和变异型TM均被糖基化且对内切糖苷酶H有抗性,这表明变异型TM以成熟形式在细胞表面表达。变异型TM蛋白显然在细胞表面表达,具有正常的PC激活辅因子活性。TM变异体不太可能通过降低表达或损害PC激活辅因子活性的机制直接导致血栓形成,而PC激活辅因子活性是TM的主要抗凝活性。